Corrigendum to Management of immune-related adverse events under PD-1/PD-L1 inhibitors: Insights from a Moroccan real-world experience: Cancer Treatment and Research Communications, Volume 44, (2025), Article number 100978.
- DOI
- 10.1016/j.ctarc.2026.101104
- Published
- 2026
- Container
- Cancer treatment and research communications
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ctarc.2026.101104,
title = {Corrigendum to Management of immune-related adverse events under PD-1/PD-L1 inhibitors: Insights from a Moroccan real-world experience: Cancer Treatment and Research Communications, Volume 44, (2025), Article number 100978.},
author = {Cherradi I and Ichou M and Houssaini MS and Ismaili N},
year = {2026},
journal = {Cancer treatment and research communications},
doi = {10.1016/j.ctarc.2026.101104},
url = {https://doi.org/10.1016/j.ctarc.2026.101104}
}RIS
TY - JOUR TI - Corrigendum to Management of immune-related adverse events under PD-1/PD-L1 inhibitors: Insights from a Moroccan real-world experience: Cancer Treatment and Research Communications, Volume 44, (2025), Article number 100978. AU - Cherradi I AU - Ichou M AU - Houssaini MS AU - Ismaili N PY - 2026 JO - Cancer treatment and research communications DO - 10.1016/j.ctarc.2026.101104 UR - https://doi.org/10.1016/j.ctarc.2026.101104 ER -
APA
I, C., M, I., MS, H., & N, I. (2026). Corrigendum to Management of immune-related adverse events under PD-1/PD-L1 inhibitors: Insights from a Moroccan real-world experience: Cancer Treatment and Research Communications, Volume 44, (2025), Article number 100978.. Cancer treatment and research communications. https://doi.org/10.1016/j.ctarc.2026.101104
Source records
- pubmed · retrieved 2026-09-27T00:34:05.423Z